Note 5 - Collaboration and License Agreement 1 (Details Textual) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended		14 Months Ended
	Nov. 06, 2020	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021
Revenue from Contract with Customer, Excluding Assessed Tax, Total			$ 7,442	$ 5,685
Contract with Customer, Liability, Current			4,571	2,552	$ 4,571
Contract with Customer, Liability, Noncurrent			3,548	3,763	3,548
3D Medicines, Inc [Member]
Proceeds from Collaborators			9,000		21,000
Collaborative Agreement, Maximum Clinical Development, Regulatory and Commercial Milestone Payments	$ 207,000
Collaborative Agreement, Royalty, Period After First Commercial Sale of Product (Year)	10 years
Revenue, Remaining Performance Obligation, Amount			21,000		21,000
Proceeds from Milestone Achievement		$ 6,000
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price			5,000
Contract with Customer, Liability, Total			8,100	6,300	8,100
Contract with Customer, Liability, Current			4,600	2,600	4,600
Contract with Customer, Liability, Noncurrent			3,500	3,700	3,500
Contract with Customer, Liability, Revenue Recognized			1,800
3D Medicines, Inc [Member] | Research and Development Services [Member]
Revenue, Remaining Performance Obligation, Amount			11,300		11,300
Revenue from Contract with Customer, Excluding Assessed Tax, Total			3,200	100
3D Medicines, Inc [Member] | License [Member]
Revenue, Remaining Performance Obligation, Amount			9,700		$ 9,700
Revenue from Contract with Customer, Excluding Assessed Tax, Total			4,200	5,600
Proceeds from Milestone Achievement			$ 6,000	$ 3,000